MCO
59
3
CNP
62
12
CME
46
3
HCA
44
-4
BLK
69
5
IRM
31
3
TSN
42
2
EXR
37
6
YUM
58
2
NTAP
46
3
SO
51
3
GLW
49
3
WFC
61
3
GM
65
2
PHM
46
3
LLY
68
4
RL
56
-3
PEP
41
-7
HES
54
-2
PCG
50
5
MCO
59
3
CNP
62
12
CME
46
3
HCA
44
-4
BLK
69
5
IRM
31
3
TSN
42
2
EXR
37
6
YUM
58
2
NTAP
46
3
SO
51
3
GLW
49
3
WFC
61
3
GM
65
2
PHM
46
3
LLY
68
4
RL
56
-3
PEP
41
-7
HES
54
-2
PCG
50
5
Financhill
Back

Theravance Biopharma 10K Form

Sell
39

TBPH
Theravance Biopharma

Last Price:
$11.61
Seasonality Move:
-3.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TBPH News And Ratings

See the #1 stock for the next 7 days that we like better than TBPH

TBPH Financial Statistics

Sales & Book Value

Annual Sales: $64.4M
Cash Flow: $43M
Price / Cash Flow: 17.62
Annual Sales: $3.32
Price / Book: 3.51

Profitability

EPS (TTM): -1.18000
Net Income (TTM): $-58.3M
Gross Margin: $71.9M
Return on Equity: -31.51%
Return on Assets: -16.32%

Theravance Biopharma Earnings Forecast

Key Theravance Biopharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for TBPH is 100.00%.
  • The Selling, General & Administrative Expenses for TBPH have been equal to 107.44% of Gross Profit Margin.
  • The Research & Development expenses have been 58.47% of Revenue.
  • The Net Earning history of TBPH is -87.63% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Theravance Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TBPH
CUSIP: G8807B
Website: theravance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.77
Quick Ratio: 4.64

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 12.55

TBPH Technical Analysis vs Fundamental Analysis

Sell
39
Theravance Biopharma (TBPH) is a Sell

Is Theravance Biopharma a Buy or a Sell?